<DOC>
	<DOCNO>NCT00193505</DOCNO>
	<brief_summary>In Multicenter trial , evaluate feasibility , toxicity , efficacy treatment 90Y Zevalin follow short course salvage chemotherapy patient relapsed/refractory intermediate grade B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Ifosfamide/Carboplatin/Etoposide/Rituxan Followed Zevalin Relapsed/Refractory Intermediate Grade B-Cell Lymphoma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Ifosfamide + Carboplatin + Etoposide + Rituximab Patients show response combination regimen receive 90Y Zevalin two cycle progression clearly document . In respond patient , four cycle administer , follow 90Y Zevalin .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>To include study , must meet following criterion : Intermediate grade CD20positive Bcell nonHodgkin 's lymphoma Persistent lymphoma one two previous chemotherapy regimens Patients consider candidate highdose chemotherapy Ability perform activity daily live assistance Measurable evaluable disease Age &gt; 18 year Adequate bone marrow , liver kidney function You participate study follow apply : Patients impair bone marrow reserve Female patient pregnant lactate Serious active infection time treatment Any serious underlying condition Brain meningeal ) lymphoma HIV AIDSrelated lymphoma Received external beam radiation therapy &gt; 25 % active bone marrow . History cancer , either active treated Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>